A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants

Phase 1 Completed 224 enrolled Loxo Oncology, Inc. Eli Lilly and Company · collab

RandomizedCrossoverOpen-labelBasic science

Summary

The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it, when given as different formulations. The information about any adverse effects experienced will be collected and the tolerability of selpercatinib will also be evaluated. The study may last up to 56 days including the 28 days of screening period.

Timeline

Start: 2021-10-29
Primary completion: 2022-07-19
Completion: 2022-07-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Selpercatinib	Small molecule	160 mg	Oral

Indications

No indication recorded.